Skip to main content
Clinical Trials/EUCTR2005-000260-57-DE
EUCTR2005-000260-57-DE
Active, not recruiting
Not Applicable

Randomized trial to assess efficacy and safety of an add-on treatment with zonisamide in adults with focal epileptic seizures with or without secondary generalization

Eisai GmbH0 sitesFebruary 22, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Partial epileptic seizures with or without secondary generalisation
Sponsor
Eisai GmbH
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 22, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Eisai GmbH

Eligibility Criteria

Inclusion Criteria

  • oAdult aged between 18 years and 74 years
  • oFocal epileptic seizures with or without secondary generalization
  • oPresent treatment with one or two antiepileptic drugs (constant dosage during the 8 weeks baseline phase prior to initiation of treatment with zonisamide). Stimulation of the vagus nerve is permitted and will not be counted as antiepileptic drug.
  • oAt least 6 focal or clonicotonic seizures documented completely in a seizure diary or the patient chart during the 8 weeks prospective or retrospective baseline phase
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • oEpileptic state during the past year
  • oNon\-epileptic fits
  • oGeneralized epilepsy
  • oConcomitant progressive CNS disease including progressive myoclonus epilepsy
  • oConcomitant treatment with vigabatrine and/or topiramate
  • oHepatic and/or renal insufficiency (creatinine \> 2 mg% or GPT \> 2 times ULN)
  • oBody weight less than 40 kg
  • o(History of) kidney stones; erythrocyturia; family history (in parents, children, brothers and sisters or grandparents) of kidney stones
  • o(History of) drug and/or alcohol dependence
  • oActive psychosis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Role of Raktavardhak Yoga in Pandu Vyadhi MangementHealth Condition 1: D508- Other iron deficiency anemias
CTRI/2024/05/067367DrPriti Amit Magdum
Recruiting
Phase 1
Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in PAH group I patients – TripleTREPulmonary arterial hypertension (group I)MedDRA version: 21.1Level: PTClassification code: 10064911Term: Pulmonary arterial hypertension Class: 100000004855Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
CTIS2023-504351-26-01Aop Orphan Pharmaceuticals GmbH117
Recruiting
Not Applicable
Randomized controlled trial to examine efficacy of late evening snack for the patients undergoing local treatment of hepatocellular carcinoma.hepatocellular carcinoma
JPRN-UMIN000006753Division of gastroenterology and hepatology, Kyoundo hospital.100
Active, not recruiting
Not Applicable
Evaluation of the safety and effectiveness of esmolol and metoprolol for heart rate reduction during heart CT examinatioHeart rate control of patients referred to coronary computed tomography angiography (CCTA) due to suspected coronary artery disease are to investigated with esmolol and metoprolol. Acquiring diagnostic image quality with CCTA requires relative low and stable heart rate of the patients during examination. Thus, heart rate control with beta-blocker medication (esmolol, metoprolol) is recommended. However no current guideline is available regarding esmolol administration during CCTA.MedDRA version: 14.1Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2013-000048-24-HUHear Center of Semmelweis University
Not yet recruiting
Phase 2
To study the efficacy of Bibhitaki siddha tail shiroabhyanga in the management of Khalitya with special reference to HairfallHealth Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
CTRI/2022/11/047115Vidarbha Ayurved Mahavidyalaya Amravati